The FDA may be preparing to ease restrictions on certain compounded peptides, potentially opening the door for medical spas, wellness clinics, and healthcare providers to offer treatments that have faced significant federal regulatory scrutiny in recent years. On October 14, 2026, the Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA) submitted a new policy titled “Interim Access Policy for Compounding Using Certain Peptides” to the White House Office of Information and Regulatory Affairs (OIRA) for review.
According to reporting from the Associated Press, the proposed policy could temporarily allow compounding pharmacies to prepare certain popular peptides, including BPC-157, while the FDA considers longer-term regulatory changes. For the medical aesthetics and wellness industry, this is a significant development. Peptide therapies have become increasingly popular, but uncertainty surrounding their regulatory status has created substantial compliance challenges for healthcare providers.
However, the proposed policy has not yet been released, and its submission does not mean previously restricted peptides are now permitted for compounding. Understanding what may change, what remains restricted, and how to prepare will be essential for practices considering peptide treatments.
What Is the FDA’s New Interim Peptide Access Policy?
The proposed policy, identified as RIN 0910-ZD94, was submitted for executive review on October 14, 2026. The publicly available filing identifies the action as a notice but does not include the full policy language or specify which peptides would be covered. Based on current reporting, the FDA is considering an approach known as enforcement discretion.
Under this approach, the FDA could temporarily decline to pursue enforcement against qualifying compounding pharmacies preparing certain peptides, even though those substances have not been formally added to the FDA’s list of bulk drug substances eligible for compounding. This distinction matters. Enforcement discretion does not mean FDA approval, and it does not permanently change federal compounding law. Instead, it allows the agency to establish temporary enforcement priorities while considering whether certain substances should become eligible for compounding through the formal regulatory process.
The policy could provide a pathway for pharmacies and healthcare practices to access certain peptides under specified conditions. However, the extent of that access will depend entirely on the final language issued by the FDA.
Until that guidance is published, practices should continue operating under existing federal and state requirements.
Why Has Peptide Compounding Been So Restricted?
Peptides have attracted considerable interest in the medical aesthetics, regenerative medicine, and wellness industries. Certain peptides are marketed for purposes involving recovery, inflammation, metabolism, cognitive function, and other health-related goals.
However, growing demand has also raised questions about safety, product quality, and the legal framework governing compounded peptide products. Beginning in 2023, the FDA placed numerous peptide substances in Category 2 of its interim list of bulk drug substances nominated for use in compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act.
Category 2 identifies substances that the FDA has determined raise significant safety concerns. Substances in this category are not eligible for the agency’s interim enforcement discretion applicable to certain nominated bulk drug substances. This created substantial challenges for compounding pharmacies and healthcare practices that had previously incorporated these peptides into their services.
What Changed in April and July 2026?
In April 2026, the FDA removed twelve peptides from Category 2 after their nominations were withdrawn. These included several substances frequently discussed in the wellness industry, such as BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and certain injectable forms of GHK-Cu.
However, removal from Category 2 did not automatically make these peptides eligible for compounding. Under Section 503A, bulk drug substances generally must satisfy specific statutory requirements, including having an applicable USP or NF monograph, being a component of an FDA-approved drug, or appearing on the FDA’s established 503A bulk drug substances list.
In July 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) took another important step by voting to recommend that six peptides be added to the 503A bulk drug substances list:
- BPC-157
- TB-500 (thymosin beta-4 fragment)
- KPV
- MOTS-c
- Semax
- Epitalon
The committee voted against recommending a seventh peptide, Emideltide (DSIP).
Although these recommendations represented a meaningful development, advisory committee votes are not binding on the FDA and do not independently authorize compounding. The newly submitted interim access policy appears to be the next step in addressing the regulatory uncertainty surrounding these substances.
The FDA has not publicly confirmed which peptides will be included in the proposed interim policy. Practices should not assume that all six peptides recommended by the advisory committee will be covered.
What Could This Mean for Med Spas and Wellness Clinics?
If the FDA implements the policy as reported, qualifying compounding pharmacies may have greater flexibility to prepare certain peptides for patient use. For healthcare practices, this could create opportunities to evaluate or expand peptide-related services. However, any expansion would need to be approached carefully. One of the most important considerations is that a change in federal enforcement policy does not eliminate the other legal obligations involved in offering a medical service.
There are several areas practices should pay particular attention to.
1. Compounding Pharmacy Requirements Will Still Apply
Even if the FDA expands access to certain peptides, practices must continue to evaluate whether their products are being prepared and distributed through legally compliant channels.
Section 503A compounding pharmacies generally prepare medications pursuant to valid patient-specific prescriptions, while Section 503B outsourcing facilities operate under a separate federal framework. These facilities are subject to different requirements, including separate rules governing the bulk drug substances they may use. An interim policy addressing 503A pharmacies would not automatically extend to 503B outsourcing facilities unless the FDA expressly provides for that coverage.
Practices should also verify pharmacy licensure, applicable sourcing requirements, pharmaceutical-grade ingredients, and appropriate quality documentation, including certificates of analysis. The existence of a new FDA policy would not make every peptide supplier or compounded product compliant.
2. Research-Grade Peptides Remain a Significant Legal Risk
One of the most concerning developments in the peptide industry has been the sale and use of products labeled “For Research Use Only” or “Not for Human Consumption.” These labels do not automatically exempt products from FDA regulation when the surrounding circumstances establish that they are intended for human use. The FDA has continued to pursue enforcement against companies marketing unapproved peptide products, including vendors attempting to rely on research-use disclaimers.
An interim policy allowing certain licensed pharmacies to compound specified peptides would not authorize medical practices to purchase research-grade products from unregulated suppliers and administer them to patients. For medical directors and licensed healthcare providers, using improperly sourced peptides may create exposure to FDA enforcement, state medical board investigations, professional discipline, and potential liability arising from patient injuries.
Practices should carefully review their existing suppliers and avoid assuming that a research-use label provides legal protection.
3. State Medical and Pharmacy Board Requirements Still Matter
Federal policy is only one part of the regulatory analysis. Even if the FDA exercises enforcement discretion for certain peptides, state boards of medicine, nursing, and pharmacy retain authority over the practice of medicine, prescribing, compounding, dispensing, and professional licensing.
States may impose requirements that are more restrictive than the federal framework. For example, a peptide that falls within a federal enforcement discretion policy may still raise concerns under state prescribing standards, pharmacy regulations, or professional scope-of-practice rules. Practices operating in multiple states must evaluate the requirements in each jurisdiction rather than relying on a single nationwide compliance approach. Medical directors should also review whether their current delegation and supervision arrangements appropriately address peptide-related services.
4. Patient Consent Does Not Replace Regulatory Compliance
Informed consent is particularly important when practices offer compounded medications that have not undergone the FDA’s approval process.
Patients should understand that compounded drugs are not FDA-approved and that the FDA has not evaluated the finished compounded product for safety, effectiveness, or quality before marketing. Consent materials should accurately explain the treatment, potential risks, limitations of available clinical evidence, and other information relevant to the patient’s decision. However, having a patient sign a consent form does not make an otherwise noncompliant treatment lawful. We frequently emphasize this distinction when advising healthcare practices. Consent forms are an important part of risk management, but they cannot resolve improper sourcing, unauthorized prescribing, scope-of-practice violations, or other regulatory deficiencies.
Practices considering new peptide offerings should review their consent materials alongside their clinical protocols and regulatory compliance procedures.
5. Advertising and Marketing Claims Need Careful Review
If access to certain peptides expands, practices may be eager to begin promoting new treatments. However, a federal enforcement discretion policy should not be marketed as FDA approval.
Statements suggesting that a compounded peptide is “FDA-approved,” has been proven effective for a particular medical condition, or is now universally legal could create regulatory concerns. Marketing claims may be reviewed under federal and state consumer protection laws, FDA requirements, and professional advertising standards. Practices should ensure that their websites, social media content, patient education materials, and promotional campaigns accurately describe the regulatory status of any peptide treatments they offer. This is particularly important for clinics promoting peptides for anti-aging, recovery, weight management, or other uses where the available clinical evidence may be limited.
What We See When Peptide Compliance Goes Wrong
At Lengea Law, we regularly assist healthcare providers with regulatory compliance, practice structure, and professional board investigations. When questions arise about a treatment, regulators may examine much more than the medication itself. They may review where the product was purchased, whether the supplier was properly licensed, who prescribed the treatment, whether the provider had appropriate authority, how the patient was evaluated, and what representations were made in the practice’s advertising and consent documents.
Medical directors may also face questions regarding their oversight of the practice and the services being performed under their supervision. These issues can become especially complicated when practices introduce new treatments before fully evaluating the applicable federal and state requirements. As the FDA considers expanding access to certain peptides, practices should use this opportunity to review their compliance procedures before making changes to their services.
How Healthcare Practices Should Prepare for the New FDA Policy
Although the interim access policy has not yet been published, there are several steps medical spas, wellness clinics, and healthcare providers can take now.
Review current peptide offerings and suppliers. Identify which peptides your practice currently offers, where they are sourced, and whether the applicable federal and state requirements are being satisfied. Verify that pharmacies are appropriately licensed and that products are supported by necessary quality and sourcing documentation.
Evaluate prescribing and clinical protocols. Confirm that patient evaluations, prescribing practices, medical documentation, delegation arrangements, and supervision requirements comply with applicable state law and professional standards.
Update patient consent materials. Ensure that existing consent forms accurately describe the treatment, its regulatory status, known risks, and limitations of available clinical evidence.
Review marketing materials. Avoid claims suggesting that compounded peptides are FDA-approved or that the proposed policy has already authorized previously restricted treatments.
Monitor the final FDA guidance. The published policy will determine which substances are covered, whether any restrictions apply to their intended uses, which compounding facilities qualify, and what conditions must be satisfied.
Consult healthcare regulatory counsel before expanding services. Practices considering peptide treatments should evaluate their proposed offerings under both federal and state law before introducing new protocols or advertising new services.
What Happens Next?
The FDA’s submission of the Interim Access Policy for Compounding Using Certain Peptides represents an important development in the ongoing debate over peptide access. If implemented as reported, the policy could provide a temporary pathway for certain peptides to be compounded while the FDA continues evaluating their long-term regulatory status.
However, the final policy could include limitations, additional requirements, or a narrower list of substances than currently anticipated. Because enforcement discretion does not permanently change the law, the FDA could also revise or withdraw the policy in the future.
For healthcare providers, this means that any new peptide service should be evaluated with both immediate compliance requirements and longer-term regulatory uncertainty in mind. Practices should wait for the official guidance before making significant changes to their prescribing protocols, supplier relationships, or treatment offerings.
How Lengea Law Can Help
As federal policy surrounding peptides continues to evolve, medical spas, wellness clinics, and healthcare providers need to understand how these developments affect their businesses.
Lengea Law works with healthcare practices nationwide on peptide compliance, compounding regulations, medical director arrangements, clinical protocols, patient consent documents, and state licensing requirements. Whether your practice currently offers peptide treatments or is considering introducing them, our team can help you evaluate your regulatory obligations, review your existing operations, and prepare for potential changes in federal policy.
If you have questions about peptide compounding or want to ensure your practice is prepared for the FDA’s anticipated guidance, contact our team to schedule a consultation. We look forward to assisting your practice in navigating these developments while maintaining compliance with applicable healthcare laws and regulations.
Disclaimer: This article is provided for general informational purposes only and does not constitute legal advice. Federal and state laws governing peptide compounding, prescribing, and administration are subject to change. Healthcare providers should consult qualified legal counsel regarding their specific circumstances before offering or modifying peptide-related services.